ePRO for Adjuvant Therapy of Colorectal Adenocarcinoma

  • STATUS
    Recruiting
  • End date
    Sep 30, 2024
  • participants needed
    270
  • sponsor
    Zhejiang University
Updated on 22 September 2021
platelet count
oxaliplatin
neutrophil count
adjuvant therapy
adenocarcinoma
adjuvant chemotherapy
colorectal adenocarcinoma

Summary

It is a multi-centric randomized controlled trial. The goal of this study is to observe the improvement of QoL using ePRO to manage patients with colorectal cancer who received Oxaliplatin-based adjuvant chemotherapy.The prognosis will also be studied.

Description

The most of advanced colorectal carcinoma are underwent postoperative chemotherapy. Adverse events (AE) during chemotherapy disrupt treatment and impair the patients' quality of life(QoL). Under usual care, the patients are largely required to self-monitor symptoms at home. Patients can lack confidence in making decisions between obtaining clinical support or self-managing and can delay seeking medical advice, heightening the risk of symptom escalation and hospital admissions and impact the efficacy of chemotherapy finally. There is growing evidence that the utilisation of patient-reported outcome(PRO) measures can aid the timely identification of physical and psychosocial disorders, facilitate patient-doctor communication and assist decision-making. There has been a drive to develop electronic systems(ePRO) to allow remote real-time patient monitoring during cancer therapy. Positive patient benefit (including QOL and survival) was recently reported in a US trial of an online system for metastatic cancer treatment.

The trial is a prospective randomised two-arm parallel group design study with repeated measures and mixed methods. Participants (adult patients with colorectal cancer on adjuvant chemotherapy) are randomised to receive the ePRO intervention or usual care over 24 weeks of treatment. Participants in the intervention arm receive training in using the ePRO APP system to provide routine weekly adverse event reports from home. Hospital staff can access ePRO reports via APP and use the information during consultations or phone calls or message with patients. The overall target sample for the trial is N = 270. The primary outcome of is quality of life (EORTC QLQ-C30/CR29) with secondary outcomes including the proportion of completed chemotherapy, AE, DFS, OS and patient self-efficacy. Outcome data is collected at baseline, 3, 6 and 12 months. The intervention is also being evaluated via end of study interviews with patient participants and clinical staff.

Details
Condition Rectal disorder, Colorectal Cancer, Colon Cancer Screening, Rectal Disorders, Colon cancer; rectal cancer, colorectal cancers
Treatment Electronic Patients Reported Outcomes
Clinical Study IdentifierNCT04069455
SponsorZhejiang University
Last Modified on22 September 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

18 to 75 years old (inclusive), regardless of gender
Patients with colorectal cancer diagnosed by cytology or histopathology
The patient underwent radical surgery for cancer. Radical surgery is defined as routine laparotomy or laparoscopic radical surgery for the purpose of radical
The ECOG performance status is 0 to 2 points and able to receive adjuvant chemotherapy
Patients must be randomized within 2 months after the surgery
According to the investigator's judgment, the patient has recovered from surgical side effects after radical surgery (e.g., the wound has healed fully without complications)
Oxaliplatin regimen is planned to be used for postoperative adjuvant chemotherapy for 3 to 6 months
The blood pregnancy test results of women of childbearing age must be negative within 7 days prior to randomization
The main organs function well. That is, the relevant inspection indexes within 14 days prior to enrollment meet the following requirements
Routine blood test: i. Leukocyte 4.0109/L; ii. Neutrophil count > 1.5109/L; iii. Blood platelet count > 80109/L; iv. Hemoglobin > 90 g/L (No blood transfusion in 14 days); b) Biochemistry test: i. TBil 1.5ULN (upper limit of normal); ii. Blood glutamic alanine aminotransferas (ALT) or serum aspartate aminotransferase (AST) 2.5ULN; iii. Endogenous creatinine clearance rate 60 ml/min (Cockcroft-Gault formula); c) Cardiac doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) 50%
The patient has provided written informed consent prior to any study-specific procedures, and is willing and able to be present during the study and follow the study procedure during treatment and follow-up

Exclusion Criteria

<18 years old or >75 years old
Other tumors except gastric and colorectal cancer
Metastasis has occurred
Female during pregnancy or lactation
A history of other malignant tumors within 5 years, except for adequately treated basal cell carcinoma or squamous cell carcinoma or carcinoma in situ
The patient is known to be allergic to oxaliplatin, 5-FU, folinic acid or any excipients of these products
Evidence of any severe or uncontrolled systemic disease, including but not limited to
Unstable or decompensated respiratory, cardiac, liver or kidney disease
HIV infection
Uncontrol high blood pressure, diabetes
Severe arrhythmia
Massive active bleeding
A history of alcohol abuse or drug abuse
As judged by the investigator, there is a low likelihood of enrollment (including inability to understand study requirements, poor compliance, infirmity, inability to ensure that the protocol can be followed as required, etc.), or there are other factors considered by the investigator to be unsuitable for this study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note